By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: Milestone Scientific Schedules Second Quarter 2025 Financial Results and Business Update Conference Call
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > Health > Milestone Scientific Schedules Second Quarter 2025 Financial Results and Business Update Conference Call
Milestone Scientific Schedules Second Quarter 2025 Financial Results and Business Update Conference Call
Health

Milestone Scientific Schedules Second Quarter 2025 Financial Results and Business Update Conference Call

GlobeNews Wire
Last updated: 14/08/2025 12:36 AM
GlobeNews Wire
Published: 14/08/2025
Share
SHARE

August 13, 2025 11:45 ET  | Source: Milestone Scientific, Inc.

ROSELAND, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:00 AM Eastern Time on Friday, August 15th, 2025, to discuss the company’s financial results for the second quarter ended June 30, 2025, as well as the company’s corporate progress and other developments.

The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 470429. A webcast and replay of the call may be accessed at Webcast URL: https://www.webcaster4.com/Webcast/Page/2306/52876.

An audio replay of the call will be available through Friday, August 29th, 2025, and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and by entering the access code: 52876.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS), a technology-focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical, dental and cosmetic applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.

Contact:
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020

Anteris Announces Results for the Second Quarter of 2025
BrowserStack Becomes the First Platform to Enable Playwright Testing on Real iOS Devices with Safari
Start with $100 and Earn Daily: How AIXA Miner Opens Crypto Income to All
IBM and Cisco Announce Plans to Build a Network of Large-Scale, Fault-Tolerant Quantum Computers
Hangyo Ice Creams Expands Production Capacity as Demand Soars Across Southern India
TAGGED:2025andBusinesscallconferencefinancialmilestonenewsNYSE:MLSSquarterresultsschedulesscientificsecondupdateUS59935P2092
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
CGTN: V-Day gala honors history, promotes path of peace
Entertainment

CGTN: V-Day gala honors history, promotes path of peace

PRNW Agency
PRNW Agency
04/09/2025
Unyte Health Launches Sonocea Enhanced Rest and Restore Protocol: Revolutionary Approach for Nervous System Regulation
Precipio Enters Into Agreement With Warrant Holder To Exercise Majority Of Warrants As Cashless
Health Canada Grants Authorization for LEQEMBI (lecanemab) for the Treatment of Early Alzheimers Disease
Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?